Literature DB >> 24557084

Growth of geographic atrophy on fundus autofluorescence and polymorphisms of CFH, CFB, C3, FHR1-3, and ARMS2 in age-related macular degeneration.

Josemaria Caire, Sergio Recalde, Alvaro Velazquez-Villoria, Laura Garcia-Garcia, Nicholas Reiter, Jaouad Anter, Patricia Fernandez-Robredo.   

Abstract

IMPORTANCE: Identification of the genetic risk factors that contribute to geographic atrophy (GA) could lead to advancements in interventional trials and/or therapeutic approaches for combating vision loss.
OBJECTIVE: To investigate whether single-nucleotide polymorphisms (SNPs) are associated with the presence and progression of established GA in age-related macular degeneration (AMD). DESIGN, SETTING, AND PARTICIPANTS: Prospective, controlled, multicenter study of 154 patients with GA/AMD and 141 age-matched control participants at 8 Spanish hospitals. MAIN OUTCOMES AND MEASURES: Samples of DNA were collected to analyze SNPs within AMD-related genes (CFH, CFB, C3, FHR1-3, and ARMS2). Fundus autofluorescence imaging was used to evaluate GA progression during a 2-year period in 73 patients with GA/AMD. Finally, logistic regression was used to analyze the associations of SNPs, age, body mass index, and cigarette smoking with the rate of progression and relative growth of GA.
RESULTS: This case-control analysis revealed a significant (P < .05) association between the presence of GA and SNPs within CFH, ARMS2, and FHR1-3. Moreover, logistic regression analysis identified significant associations of the rate of progression with genetic polymorphisms (CFH-402His [P = .04] and CFH-62Ile [P = .04]) and demographic factors (sex [P = .02] and age [P = .02]), whereas relative growth was associated with 1 polymorphism (CFB-32Gln [P = .04]).Conclusions and Relevance Taken together, our findings confirm that genetic risk factors related to the presence of GA are not identical to those associated with GA progression. In fact, we demonstrate that gene variants of CFH and CFB, as well as demographic risk factors, confer significant risk for GA progression (both rate of progression and relative growth) within a Spanish population.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24557084     DOI: 10.1001/jamaophthalmol.2013.8175

Source DB:  PubMed          Journal:  JAMA Ophthalmol        ISSN: 2168-6165            Impact factor:   7.389


  13 in total

1.  Incidence and Growth of Geographic Atrophy during 5 Years of Comparison of Age-Related Macular Degeneration Treatments Trials.

Authors:  Juan E Grunwald; Maxwell Pistilli; Ebenezer Daniel; Gui-Shuang Ying; Wei Pan; Glenn J Jaffe; Cynthia A Toth; Stephanie A Hagstrom; Maureen G Maguire; Daniel F Martin
Journal:  Ophthalmology       Date:  2016-10-27       Impact factor: 12.079

2.  Progression of Geographic Atrophy in Age-related Macular Degeneration: AREDS2 Report Number 16.

Authors:  Tiarnan D Keenan; Elvira Agrón; Amitha Domalpally; Traci E Clemons; Freekje van Asten; Wai T Wong; Ronald G Danis; SriniVas Sadda; Philip J Rosenfeld; Michael L Klein; Rinki Ratnapriya; Anand Swaroop; Frederick L Ferris; Emily Y Chew
Journal:  Ophthalmology       Date:  2018-07-27       Impact factor: 12.079

3.  Growth of geographic atrophy in the comparison of age-related macular degeneration treatments trials.

Authors:  Juan E Grunwald; Maxwell Pistilli; Gui-Shuang Ying; Maureen G Maguire; Ebenezer Daniel; Daniel F Martin
Journal:  Ophthalmology       Date:  2014-12-24       Impact factor: 12.079

4.  Understanding the patient's lived experience of neovascular age-related macular degeneration: a qualitative study.

Authors:  C McCloud; S Lake
Journal:  Eye (Lond)       Date:  2015-09-18       Impact factor: 3.775

5.  Geographic atrophy severity and mortality in age-related macular degeneration.

Authors:  Aneesha Ahluwalia; Liangbo L Shen; Evan M Chen; Mengyuan Sun; Michael M Park; Benjamin K Young; Lucian V Del Priore
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2021-03-19       Impact factor: 3.535

6.  QUANTITATIVE ANALYSIS OF LONGITUDINAL CHANGES IN MULTIMODAL IMAGING OF LATE-ONSET RETINAL DEGENERATION.

Authors:  Elliott K Vanderford; Tharindu De Silva; Dominique Noriega; Mike Arango; Denise Cunningham; Catherine A Cukras
Journal:  Retina       Date:  2021-08-01       Impact factor: 3.975

7.  Clinical and genetic factors associated with progression of geographic atrophy lesions in age-related macular degeneration.

Authors:  Felix Grassmann; Monika Fleckenstein; Emily Y Chew; Tobias Strunz; Steffen Schmitz-Valckenberg; Arno P Göbel; Michael L Klein; Rinki Ratnapriya; Anand Swaroop; Frank G Holz; Bernhard H F Weber
Journal:  PLoS One       Date:  2015-05-11       Impact factor: 3.240

Review 8.  Potential role of lampalizumab for treatment of geographic atrophy.

Authors:  William Rhoades; Drew Dickson; Diana V Do
Journal:  Clin Ophthalmol       Date:  2015-06-11

9.  Progression Rate From Intermediate to Advanced Age-Related Macular Degeneration Is Correlated With the Number of Risk Alleles at the CFH Locus.

Authors:  Rebecca J Sardell; Patrice J Persad; Samuel S Pan; Patrice Whitehead; Larry D Adams; Reneé A Laux; Jorge A Fortun; Milam A Brantley; Jaclyn L Kovach; Stephen G Schwartz; Anita Agarwal; Jonathan L Haines; William K Scott; Margaret A Pericak-Vance
Journal:  Invest Ophthalmol Vis Sci       Date:  2016-11-01       Impact factor: 4.799

Review 10.  Geographic atrophy in patients with advanced dry age-related macular degeneration: current challenges and future prospects.

Authors:  Ronald P Danis; Jeremy A Lavine; Amitha Domalpally
Journal:  Clin Ophthalmol       Date:  2015-11-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.